Venous Thromboembolism Treatment Market (2023-2030)
The Venous Thromboembolism Treatment Market is projected to reach $4.40 billion by 2030, at a CAGR of 7.2% from 2023 to 2030.
- Published
- Dec 2023
- Pages
- 158
- Format
- PDF + Excel
- Report ID
- MRHC - 1041062
- Base year
- 2023
- 2030 · FORECAST
- $4.40B
- 2030
- $4.40B
- CAGR 2023–2030
- 7.2%
2023–2030 forecast at 7.2% CAGR · hover a bar for the value
Key highlights
The Thrombectomy Devices Segment is Expected to Account for the Largest Share of the Market in 2023
The Deep Vein Thrombosis Segment is Expected to Account for the Largest Share of the Market in 2023
The Hospitals Segment is Expected to Account for the Largest Share of the Market in 2023
Asia-Pacific: Fastest Growing Regional Market
Report summary
| Particulars | Details |
|---|---|
| Page No | 157 |
| Format | |
| Forecast Period | 2023-2030 |
| Base Year | 2023 |
| CAGR | 7.2% |
| Market Size (Value) | $4.40 billion |
| Market Size (Volume) | NA |
| Segments Covered | Device, Application, and End User |
| Countries Covered | North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Latin America, and the Middle East & Africa. |
| Key Companies | ALN Implants chirurgicaux (ALN Surgical Implants) (France), AngioDynamics, Inc. (U.S.), Argon Medical Devices, Inc. (U.S.), ArjoHuntleigh AB (Sweden), Boston Scientific Corporation (U.S.), Cardinal Health, Inc. (U.S.), Cook Group Incorporated (U.S.), Koninklijke Philips N.V. (Netherlands), DS MAREF Co., LTD (South Korea), Enovis Corporation (U.S.), LifeTech Scientific Corporation (China), Medtronic plc (Ireland), and Stryker Corporation (U.S.) |
Report overview
Segments covered: device, application, end user. Regions: North America, Europe, Asia-Pacific.
Venous thromboembolism occurs when a blood clot forms in a vein, obstructing the blood flow and posing a potentially life-threatening risk. Several devices and drugs are employed for the prevention and treatment of venous thromboembolism. The devices considered within this scope are utilized for both the prevention and treatment of venous thromboembolism and encompass compression pumps, thrombectomy devices, inferior vena cava filters, and stockings, among others.
The high prevalence of venous thromboembolism, rising incidence of cancer, growing prevalence of secondary risk factors such as diabetes and obesity, increase in orthopedic surgical procedures, and the rising demand for minimally invasive treatment procedures are the key factors driving the growth of the venous thromboembolism treatment market. Furthermore, the growing accessibility and affordability of treatment options, advancements in VTE diagnosis and treatment methods, and the market expansion in emerging economies are expected to create market growth opportunities.
However, instances of product failure and product recalls may restrain the market’s growth. Additionally, lack of awareness about venous thromboembolism and increasing awareness of probable side effects of compression garments are major challenges for market growth.
Report infographic
Market dynamics
1 factors across 1 forceGrowing Accessibility and Affordability of Treatment Options to Offer Growth Opportunities to Market Players
Access to VTE treatments is increasing due to the rising disposable incomes and growing awareness about the importance of early disease treatment. Government agencies are launching health campaigns to raise awareness about venous thromboembolism. For instance, the International Society on Thrombosis and Haemostasis (ISTH) (U.S.) conducted a global campaign on 13th October 2023 to raise awareness regarding conditions caused by thrombosis, a disorder responsible for one in four deaths worldwide. Most health insurance companies and Medicare cover DVT treatment costs, contributing to the affordability of VTE treatments.
There is a notable transition in the treatment of VTE from traditional hospital settings to outpatient environments, including ambulatory care and home care settings. This shift is largely driven by the cost-effectiveness of outpatient settings compared to hospitals. Expenses such as nursing costs, hospital stays, and laboratory services are generally lower in outpatient settings, enhancing the affordability of venous thromboembolism treatments for patients. This trend opens up growth opportunities for players operating in this space.
Table of contents
11 chapters · 89 sections · 158 pages · click to expandSegmental analysis
| Segment | Largest share (2023) | Fastest growth (2023–2030) |
|---|---|---|
| By Device | Thrombectomy Devices | — |
| By Application | Deep Vein Thrombosis | — |
| By End User | Hospitals | — |
By Device
- The thrombectomy devices segment is expected to account for the largest share of the market.
- The main factors contributing to the large market share of this segment are the increasing prevalence of cardiovascular diseases, growing preference for minimally invasive procedures, and launches of new thrombectomy devices.
- Thrombectomy devices are employed in the treatment of venous thromboembolism (VTE), acute stroke, pulmonary embolism (PE), and deep vein thrombosis (DVT).
- Venous thrombectomy is performed in patients with severe cases of DVT that may lead to PE.
- According to various research studies, approximately 13-31% of critically ill patients develop DVT, which requires interventional procedures like thrombectomy.
By Application
- The Deep Vein Thrombosis Segment is Expected to Account for the Largest Share of the Market in 2023
- The deep vein thrombosis (DVT) segment is expected to account for the largest share of the market.
- The large market share of this segment is attributed to the increasing prevalence of obesity, a growing geriatric population, rising cases of deep vein thrombosis due to lifestyle-related diseases, excessive alcohol consumption, and heightened awareness of DVT.
By End User
- The hospitals segment is expected to account for the largest share of the market.
- The large market share is attributed to the increasing prevalence of venous thromboembolism, the rising number of hospitals and clinics, the presence of highly skilled professionals, and the high purchasing power of hospitals.
- The easy accessibility to hospitals, coupled with a large patient population seeking comprehensive healthcare services, including diagnosis, treatment, and surgeries at a single location, also contributes to the significant market share of this segment.
Geographic analysis
Asia-Pacific
Fastest growthAsia-Pacific is slated to register the highest CAGR in the venous thromboembolism treatment market during the forecast period. The growth of this regional market can be attributed to factors such as the growing prevalence of chronic diseases, the increasing number of people living sedentary lifestyles, growing health expenditures, supportive government initiatives aimed at improving healthcare infrastructure, and rising awareness regarding venous thromboembolism. Asia-Pacific: Fastest Growing Regional Market
Competitive landscape
- ALN Implants chirurgicaux (ALN Surgical Implants) · France
- AngioDynamics, Inc. (U.S.)
- Argon Medical Devices, Inc. (U.S.)
- ArjoHuntleigh AB · Sweden
- Boston Scientific Corporation (U.S.)
- Cardinal Health, Inc. (U.S.)
- Cook Group Incorporated (U.S.)
- Koninklijke Philips N.V. · Netherlands
- DS MAREF Co., LTD · South Korea
- Enovis Corporation (U.S.)
- LifeTech Scientific Corporation · China
- Medtronic plc · Ireland
- Stryker Corporation (U.S.)
Frequently asked questions
This study offers a detailed assessment of the venous thromboembolism treatment market, including the market sizes & forecasts for various segmentations like device, application, and end user. The venous thromboembolism treatment market report also involves the value analysis of the market at the regional and country levels.
Cite this report
Meticulous Research. (2023). Venous Thromboembolism Treatment Market - Global Opportunity Analysis and Industry Forecast (2023-2030) (Report No. MRHC - 1041062). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/venous-thromboembolism-treatment-market-5745